Accelerate to discover
Related topics
IncuCyte white paper: live-cell analysis for Neuroscientists
Mar 20, 2019
Stem cell technologies using iPSCs allow researchers to create differentiated neurons and support cells to study human...
Cell plasticity associated to circulating tumor cells from prostate cancer patients
Mar 13, 2019
Treatment resistance is associated with tumor cells molecular plasticity. In metastatic castration resistant prostate...
Enhanced uptake of luminescent quantum dots by live cells
Mar 1, 2019
The steady progress made over the past threedecades in growing a variety of inorganic nanomaterials, with discreet...
Fat-water separation Imaging in Preclinical MRI
Mar 1, 2019
Non-invasive in vivo phenotyping of adipose tissue deposits in small animal models is of great importance in...
Feb 15, 2019
The CellRad system allows you to irradiate cells in your lab without compromising sterility or security. A smaller,...
New technique for dynamic monitoring of liquid tumor Cytotoxicity
Feb 12, 2019
To develop and validate immuno-oncology therapies, scientists must understand the full dynamics of cytotoxic effectors...
Small animal 13C-hyperpolarized MRI
Feb 8, 2019
13C-Hyperpolarized molecules provide a unique signature for molecular processes relevant to a range of disease...
Oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts
Jan 30, 2019
Pancreatic ductal adenocarcinoma has been increasing by 0.5% per year in the United States. This study describes the...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
